(2 boxes, 4 pens, 10% off) Manjaro Mianjianle/Tirzepatide/Tirzepatide/Tirzepatide/Slimming Pen/Tirzepatide 2.5mg Subcutaneous Injection Long-acting GIP/GLP-1 Receptor Agonist Type 2 Diabetes Blood Sugar Control Fat Reduction Weight Loss Insulin Weight Loss

Regulatory Classification: Potent Drug/Prescription Drug Note: Use only under the prescription of a physician or other qualified prescriber.

Long-acting GIP/GLP-1 receptor agonist

2.5mg/5mg, two per box

Injection

Tirzepatide additives: Disodium hydrogen phosphate heptahydrate 0.7mg, Sodium chloride 4.1mg, Hydrochloric acid (appropriate amount), Sodium hydroxide (appropriate amount)

Efficacy or Effect: Type 2 Diabetes. Precautions related to efficacy or effect: The use of this drug should be considered only when diet and exercise therapies, which are fundamental to diabetes treatment, have been sufficiently implemented and are not effective. Weight reduction in adults.

The usual maintenance dose for adults is 5 mg of tirzepatide administered subcutaneously once weekly. However, treatment should be initiated at 2.5 mg once weekly, and after 4 weeks of administration, the dose can be increased to 5 mg once weekly. The dose may be adjusted according to the patient's condition, but if 5 mg once weekly is insufficient, the dose can be increased by 2.5 mg every 4 weeks or longer. However, the maximum dose should not exceed 15 mg once weekly.

Prescribe only for patients with a BMI of 23 or higher. For weight loss purposes, co-administration with birth control pills (oral contraceptives) and warfarin is not recommended. While not a contraindication, co-administration will reduce the effectiveness of birth control pills and warfarin due to delayed gastric emptying. Due to its blood sugar lowering effect, it cannot be used in combination with other antidiabetic drugs, including SGLT2 inhibitors.

Contraindications: (Do not administer to the following patients) Patients with a history of hypersensitivity to the components of this drug. Patients with diabetic ketoacidosis, diabetic coma or precoma, or type 1 diabetes mellitus. [Immediate treatment with insulin preparations is essential, so this drug should not be administered.] Severe infections, surgical emergencies, etc. [Blood glucose management with insulin preparations is desirable, so administration of this drug is not suitable.]